Bathi saben saham sajrone rolas wulan pungkasan: Tharimmune Inc (THAR)

Tharimmune, Inc. (THAR) develops biologics to combat cancer and inflammation, protecting its margins through patents. The GURU.Markets service features a linear chart of the moving average profit per unit, where the current mark is -3.94. Tharimmune, Inc. (THAR) diversifies its risks through pruritus therapy and liver oncology, relying on a stable staff of antibody and clinical testing experts.

Annual net income per share reflects the capital generation efficiency of Tharimmune, Inc. (THAR) relative to its total shares outstanding. This metric is calculated by dividing the final financial result by the number of securities. By analyzing the company's specific annual income, an investor assesses the business's ability to cover operating expenses. In the absence of sales, rising costs for biotechnological tests directly increase the loss per share. This negative trend confirms the high cost of scaling the clinical pipeline.